Cabio Biotech Wuhan Co Ltd (688089) — Cash Flow-to-Debt Ratio
Cabio Biotech Wuhan Co Ltd (688089) has a Cash Flow-to-Debt Ratio of 0.31x as of September 2025, meaning its operating cash flow of CN¥56.10 Million could theoretically repay 0% of its total liabilities (CN¥183.42 Million) in one year. Check Cabio Biotech Wuhan Co Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cabio Biotech Wuhan Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Cabio Biotech Wuhan Co Ltd across 12 annual periods. Also explore Cabio Biotech Wuhan Co Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Cabio Biotech Wuhan Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Cabio Biotech Wuhan Co Ltd. For market capitalisation and broader financial context, see how much is Cabio Biotech Wuhan Co Ltd worth.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.48x | CN¥173.04 Million | CN¥117.27 Million | ▲ +151.9% |
| 2023 | 0.59x | CN¥68.89 Million | CN¥117.60 Million | ▼ -38.3% |
| 2022 | 0.95x | CN¥176.40 Million | CN¥185.77 Million | ▼ -38.7% |
| 2021 | 1.55x | CN¥103.29 Million | CN¥66.68 Million | ▼ -37.0% |
| 2020 | 2.46x | CN¥145.88 Million | CN¥59.30 Million | ▼ -10.0% |
| 2019 | 2.73x | CN¥131.95 Million | CN¥48.26 Million | ▲ +41.6% |
| 2018 | 1.93x | CN¥106.16 Million | CN¥54.99 Million | ▼ -19.5% |
| 2017 | 2.40x | CN¥100.66 Million | CN¥41.98 Million | ▲ +184.5% |
| 2016 | 0.84x | CN¥62.53 Million | CN¥74.17 Million | ▲ +61.9% |
| 2015 | 0.52x | CN¥44.58 Million | CN¥85.60 Million | ▼ -53.3% |
| 2014 | 1.12x | CN¥46.34 Million | CN¥41.52 Million | ▲ +12.2% |
| 2013 | 0.99x | CN¥39.48 Million | CN¥39.68 Million | — |